0001209191-19-021883.txt : 20190329 0001209191-19-021883.hdr.sgml : 20190329 20190329201345 ACCESSION NUMBER: 0001209191-19-021883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190327 FILED AS OF DATE: 20190329 DATE AS OF CHANGE: 20190329 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRYANT DOUGLAS C CENTRAL INDEX KEY: 0001406652 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 19718448 MAIL ADDRESS: STREET 1: C/O QUIDEL CORPORATION STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8585521100 MAIL ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-27 0 0000353569 QUIDEL CORP /DE/ QDEL 0001406652 BRYANT DOUGLAS C 12544 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 1 1 0 0 President & CEO Common Stock 2019-03-27 4 M 0 795 12.63 A 302237 D Common Stock 2019-03-27 4 S 0 795 65.03 D 301442 D Common Stock 2019-03-28 4 M 0 1335 12.63 A 302777 D Common Stock 2019-03-28 4 S 0 1335 65.062 D 301442 D Common Stock 2019-03-29 4 M 0 23120 12.63 A 324562 D Common Stock 2019-03-29 4 S 0 23120 65.696 D 301442 D Non-Qualified Stock Option 12.63 2019-03-27 4 M 0 795 0.00 D 2021-03-02 Common Stock 795 30293 D Non-Qualified Stock Options 12.63 2019-03-28 4 M 0 1335 0.00 D 2021-03-02 Common Stock 1335 28958 D Non-Qualified Stock Options 12.63 2019-03-29 4 M 0 23120 0.00 D 2021-03-02 Common Stock 23120 5838 D The weighted average sale price for these transactions was $65.03 per share, with a range of $65.00 to $65.11. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. The weighted average sale price for these transactions was $65.062 per share, with a range of $65.03 to $65.08. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. The weighted average sale price for these transactions was $65.696 per share, with a range of $65.38 to $66.29. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. 42,959 shares vested on 03/02/2013; 21,479 shares vested on 03/02/2014; 21,480 shares vested on 03/02/2015. All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan. Robert J. Bujarski, attorney-in-fact for Douglas C. Bryant 2019-03-29